Aimeike Receives Medical Device Registration Certificate for Sodium Hyaluronate Gel

Regulation
โดย 财中社·Read original
Summary · why it matters

Aimeike has obtained a medical device registration certificate from the National Medical Products Administration for its medical cross-linked sodium hyaluronate-hydroxypropyl methylcellulose gel. The registration is valid from July 28, 2026, to July 27, 2031. In the first quarter of 2026, the company achieved revenue of 634 million yuan and a net profit attributable to the parent company of 298 million yuan.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews